|1.||Iwamoto, Jun: 33 articles (10/2015 - 01/2002)|
|2.||Takeda, Tsuyoshi: 28 articles (09/2012 - 01/2002)|
|3.||Sato, Yoshihiro: 26 articles (09/2012 - 08/2004)|
|4.||Uzawa, Mitsuyoshi: 15 articles (01/2011 - 06/2003)|
|5.||Black, Dennis M: 14 articles (10/2014 - 09/2003)|
|6.||Matsumoto, Hideo: 14 articles (09/2012 - 01/2008)|
|7.||Burr, David B: 13 articles (12/2015 - 04/2007)|
|8.||Miller, Paul D: 12 articles (01/2014 - 05/2002)|
|9.||Ringe, J D: 12 articles (04/2012 - 06/2000)|
|10.||Greenspan, Susan L: 11 articles (01/2012 - 05/2002)|
01/01/2012 - "Osteoporosis screening followed by alendronate treatment is effective and highly cost-effective for postmenopausal women across a range of alendronate costs, and may be cost-saving at annual alendronate costs of $200 or less."
10/01/2005 - "Universal bone densitometry combined with alendronate therapy for those found to have osteoporosis is highly cost-effective for women aged 65 and older and may be cost saving for ambulatory women aged 85 and older (whether independently living or residing in nursing homes)."
10/01/2005 - "Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women."
07/01/2000 - "Recent results from the first megatrial of osteoporosis with >6400 participants, the Fracture Intervention Trial (FIT), have provided important advances in our understanding of osteoporosis and the efficacy of alendronate. "
01/01/2000 - "As there are no proven safe and effective treatments available for men with osteoporosis, we compared the effects of alendronate (10 mg/day) on BMD, measured using dual-energy X-ray absorptiometry, in a 12-month prospective, controlled, open label study involving (i) men with primary (n = 23) or secondary osteoporosis (n = 18), (ii) postmenopausal women with primary (n = 18) or secondary (n = 21) osteoporosis, and (iii) 29 male and 14 female untreated controls matched by age, height and weight. "
01/01/2014 - "Most studies suggested a positive short-term efficacy of alendronate treatment in reducing pain, improving articular function, slowing of bone collapse progression, and delaying the need for THA for adult AVN patients. "
01/01/2012 - "The patient's bone pain was dramatically reduced by the administration of alendronate for 7 months. "
11/01/2004 - "In contrast to placebo-treated patients (n = 20), all of the alendronate-treated patients (n = 19) exhibited a marked and sustained improvement in levels of spontaneous pain, pressure tolerance, and joint mobility, as well as a significant reduction in urinary levels of NTX at weeks 4 and 8. The improvement was maintained at week 12. "
05/24/2012 - "In a randomized trial testing alendronate, bone pain was not significantly improved. "
10/01/2005 - "After 1 year of alendronate therapy we observed a significant increase in areal and volumetric bone mineral density Z-scores (from -2.03 +/- 1.51 to -1.04 +/- 1.20, and from -1.91 +/- 1.38 to -1.33 +/- 1.30, respectively, P < 0.001), together with a significant drop in fracture rate (from 3.77 +/- 1.57 to 0.13 +/- 0.57, P < 0.000001), relief of chronic pain (from 3.83 +/- 1.44 days of pain/week to 0.73 +/- 0.77, P < 0.000001) and improvement in ambulation/mobility (P < 0.00002). "
09/01/2010 - "This prospective study, in the very early phase after initiation of glucocorticoid (GC) treatment, showed that alendronate was effective in suppressing accelerated bone resorption and subsequent decrease in bone mineral density (BMD) at the lumbar spine of patients with high-dose GC treatment. "
10/01/2010 - "After 3 months of alendronate, there was no significant reduction in the number of osteoclast precursors, osteoclast formation and viability, and cytokine levels, whereas, there was a significant reduction of bone resorption markers. "
09/01/2010 - "Alendronate was effective in suppressing bone resorption and subsequent BMD decrease at the lumbar spine in patients with high-dose GC treatment."
05/01/2000 - "The present study was designed to examine histopathologically whether local delivery of aminobisphosphonate (alendronate) could be effective in preventing the alveolar bone resorption associated with mucoperiosteal flaps. "
08/01/2007 - "Treatment with alendronate improved trabecular volume and number by reducing bone resorption, although bone formation was also reduced through coupling of bone remodeling. "
02/01/2004 - "Alendronate has been proven to be effective in the prevention and treatment of postmenopausal osteoporosis with the recommended daily dose of 10 mg. However, a constraining requirement for dosing limited its general acceptance in treatment. "
12/01/1995 - "The authors observe a significant reduction in value of the Nordin's Index (a sensible test for the screening of the "fast-losers" patients) in 10 women with post-menopausal osteoporosis after therapy with alendronate 5 mg daily per os for six months. "
12/21/1999 - "A residual effect was seen 2 years after alendronate therapy was stopped; however, continuous alendronate treatment was more effective in preventing postmenopausal bone loss than 2 years of alendronate followed by 2 years of placebo."
01/01/2002 - "Alendronate (10 mg daily) has been shown in long term clinical trials to be an effective treatment for postmenopausal osteoporosis. "
06/01/2002 - "Alendronate (Chinese national product) is effective in reducing bone turnover and promoting bone mass of postmenopausal osteoporosis."
|5.||Metabolic Bone Diseases (Osteopenia)
02/01/1998 - "In summary, this study demonstrated that alendronate therapy is highly effective in counteracting the osteopenia of OVX and glucocorticoid therapy."
07/01/2013 - "Treatment with alendronate sodium may be effective in alleviating osteopenia."
01/01/2007 - "In women with osteopenia, alendronate therapy may be cost effective in women with a T-score of -2.4SD in the US. "
12/01/2005 - "Is alendronate therapy cost-effective for postmenopausal osteopenia?"
05/01/2009 - "Alendronate infused in this manner significantly prevented the osteopenia that critically began early in the consolidation phase, though the dose used in this study was relatively low and no adverse events were noted."
|1.||risedronic acid (risedronate)
|3.||Etidronic Acid (HEDP)
|6.||Alendronate (Alendronate Sodium)
|9.||zoledronic acid (zoledronate)
|3.||Hormone Replacement Therapy (Therapy, Hormone Replacement)
|5.||Drug Therapy (Chemotherapy)